NO20001828D0 - Metode for å forhindre nefrotoksisitet forårsaket av cyklosporiner og tacrolimus - Google Patents

Metode for å forhindre nefrotoksisitet forårsaket av cyklosporiner og tacrolimus

Info

Publication number
NO20001828D0
NO20001828D0 NO20001828A NO20001828A NO20001828D0 NO 20001828 D0 NO20001828 D0 NO 20001828D0 NO 20001828 A NO20001828 A NO 20001828A NO 20001828 A NO20001828 A NO 20001828A NO 20001828 D0 NO20001828 D0 NO 20001828D0
Authority
NO
Norway
Prior art keywords
tacrolimus
administration
patient
cyclosporin
pps
Prior art date
Application number
NO20001828A
Other languages
English (en)
Other versions
NO20001828L (no
Inventor
Gary E Striker
Lilliane Striker
Kenneth H Kortright
Original Assignee
Baker Norton Pharma
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baker Norton Pharma, Us Health filed Critical Baker Norton Pharma
Publication of NO20001828D0 publication Critical patent/NO20001828D0/no
Publication of NO20001828L publication Critical patent/NO20001828L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Cephalosporin Compounds (AREA)
NO20001828A 1997-10-09 2000-04-07 Metode for Õ forhindre nefrotoksisitet forÕrsaket av cyklosporiner og tacrolimus NO20001828L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6294797P 1997-10-09 1997-10-09
US09/168,974 US6187745B1 (en) 1997-10-09 1998-10-01 Method of preventing nephrotoxicity caused by cyclosporins and tacrolimus
PCT/US1998/021313 WO1999018961A1 (en) 1997-10-09 1998-10-09 Method of preventing nephrotoxicity caused by cyclosporins and tacrolimus

Publications (2)

Publication Number Publication Date
NO20001828D0 true NO20001828D0 (no) 2000-04-07
NO20001828L NO20001828L (no) 2000-05-15

Family

ID=22045901

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20001828A NO20001828L (no) 1997-10-09 2000-04-07 Metode for Õ forhindre nefrotoksisitet forÕrsaket av cyklosporiner og tacrolimus

Country Status (24)

Country Link
US (1) US6187745B1 (no)
EP (1) EP1027053B1 (no)
JP (1) JP2001519392A (no)
KR (1) KR100515196B1 (no)
CN (1) CN1154492C (no)
AT (1) ATE269098T1 (no)
AU (1) AU748495B2 (no)
BR (1) BR9813860A (no)
CA (1) CA2304374A1 (no)
CZ (1) CZ297440B6 (no)
DE (1) DE69824619T2 (no)
DK (1) DK1027053T3 (no)
ES (1) ES2221714T3 (no)
HK (1) HK1026845A1 (no)
HU (1) HUP0003904A3 (no)
IL (1) IL135235A0 (no)
NO (1) NO20001828L (no)
NZ (1) NZ503493A (no)
PL (1) PL191993B1 (no)
PT (1) PT1027053E (no)
RU (1) RU2191020C2 (no)
SK (1) SK285332B6 (no)
UA (1) UA65587C2 (no)
WO (1) WO1999018961A1 (no)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001052867A1 (en) * 2000-01-19 2001-07-26 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Use of pentosan polysulfate to treat certain conditions of the prostate
US6613083B2 (en) * 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
CA2461730C (en) * 2001-10-19 2012-05-15 Isotechnika Inc. Novel cyclosporin analog microemulsion preconcentrates
JP2005526107A (ja) * 2002-04-16 2005-09-02 藤沢薬品工業株式会社 慢性拒絶反応を予防および／または処置するための医薬
ES2482105T3 (es) 2004-05-27 2014-08-01 Baxter International Inc. Procedimientos de tratamiento de trastornos hemorrágicos utilizando polisacáridos sulfatados
WO2010020423A2 (en) 2008-08-22 2010-02-25 Baxter Healthcare S.A. Methods for treating bleeding disorders
AU2011205271B2 (en) 2010-01-14 2014-01-30 Baxalta GmbH Methods and compositions for treating bleeding disorders
US8871741B2 (en) * 2010-01-15 2014-10-28 Icahn School Of Medicine At Mount Sinai Inhibition of TNF-α induced activation of NFKB by pentosan polysulfate
CN102327282A (zh) * 2010-09-01 2012-01-25 吴洪 戊糖多聚硫酸酯用于制备治疗糖尿病肾病的药物中的用途
DK2734213T3 (en) 2011-07-19 2018-08-13 Baxalta GmbH RESORPTION PROMOTERS ADDITIVES TO IMPROVE ORAL FORMULATION OF NON-ANTI-COATING SULPHATE POLYSACCHARIDS
CN103957875A (zh) 2011-10-05 2014-07-30 阿勒根公司 用于增强指甲健康的组合物
EP2885642B1 (en) 2012-08-14 2019-05-15 Baxalta GmbH Methods and systems for screening compositions comprising non-anticoagulant sulfated polysaccharides
WO2016099214A1 (ko) * 2014-12-18 2016-06-23 가톨릭대학교 산학협력단 메트포민을 포함하는 면역억제제로 인한 신장 독성 완화용 조성물 및 이를 포함하는 면역질환 예방 또는 치료용 조성물
KR101760510B1 (ko) 2014-12-18 2017-07-21 가톨릭대학교 산학협력단 메트포민을 포함하는 면역억제제로 인한 신장 독성 완화용 조성물 및 이를 포함하는 면역질환 예방 또는 치료용 조성물
WO2016199161A2 (en) * 2015-06-12 2016-12-15 Swati Vishal Jajodia A composition comprising pentosan polysulfate sodium for use in treatment of bladder outlet obstruction and/or lower urinary tract symptoms

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0466315A3 (en) 1990-05-30 1992-07-01 Larrian Gillespie Compositions containing xylan sulphates for affecting growth factor function and for inhibiting fibroblast proliferation
US5204329A (en) 1990-06-11 1993-04-20 Du Pont Merck Pharmaceutical Company Treatment of organ transplantation rejection
US5605938A (en) * 1991-05-31 1997-02-25 Gliatech, Inc. Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate
IT1277147B1 (it) * 1995-01-20 1997-11-04 Sigma Tau Ind Farmaceuti Uso della carnitina e i suoi derivati per ridurre gli effetti tossici della ciclosporina-a e di altri farmaci immunosoppressivi.
JPH08208489A (ja) * 1995-02-03 1996-08-13 L T T Kenkyusho:Kk 腎不全治療剤
US5643892A (en) 1995-06-07 1997-07-01 Baker Norton Pharmaceuticals, Inc. Method of treating chronic progressive vascular diseases

Also Published As

Publication number Publication date
NO20001828L (no) 2000-05-15
EP1027053A4 (en) 2002-05-22
DK1027053T3 (da) 2004-09-06
DE69824619T2 (de) 2005-06-23
PT1027053E (pt) 2004-09-30
AU748495B2 (en) 2002-06-06
UA65587C2 (en) 2004-04-15
EP1027053A1 (en) 2000-08-16
CZ297440B6 (cs) 2006-12-13
KR100515196B1 (ko) 2005-09-16
CA2304374A1 (en) 1999-04-22
AU9794398A (en) 1999-05-03
WO1999018961A1 (en) 1999-04-22
PL339774A1 (en) 2001-01-02
KR20010030749A (ko) 2001-04-16
SK4672000A3 (en) 2001-09-11
HK1026845A1 (en) 2000-12-29
EP1027053B1 (en) 2004-06-16
NZ503493A (en) 2001-11-30
ATE269098T1 (de) 2004-07-15
DE69824619D1 (de) 2004-07-22
BR9813860A (pt) 2001-03-20
HUP0003904A1 (hu) 2001-08-28
CN1154492C (zh) 2004-06-23
SK285332B6 (sk) 2006-11-03
IL135235A0 (en) 2001-05-20
US6187745B1 (en) 2001-02-13
RU2191020C2 (ru) 2002-10-20
JP2001519392A (ja) 2001-10-23
PL191993B1 (pl) 2006-08-31
ES2221714T3 (es) 2005-01-01
HUP0003904A3 (en) 2006-06-28
CN1275080A (zh) 2000-11-29
CZ20001274A3 (cs) 2001-12-12

Similar Documents

Publication Publication Date Title
AU642210B2 (en) Therapeutic use of indole-3-yl-carboxylic acid endo-8- methyl-8-aza-bicyclo(3,2,1)oct-3-yl ester
NO20001828D0 (no) Metode for å forhindre nefrotoksisitet forårsaket av cyklosporiner og tacrolimus
ES2188782T3 (es) Formulaciones farmaceuticas que contienen darifenacina.
WO2005065069A3 (en) Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
EP0794794A4 (en) METHODS, COMPOSITIONS AND KITS FOR INCREASING THE ORAL BIOVAVAILABILITY OF PHARMACEUTICALS
JP2002523370A5 (no)
CA2274510A1 (en) Treatment of osteoarthritis by administering poly-n-acetyl-d-glucosamine
US4425363A (en) Treatment of tardive dyskinesia in mammals
AU647463B2 (en) A method and a pharmaceutical preparation for treating pain
KR19980701720A (ko) 세스키테르펜 락톤 및 비타민 b 복합체를 함유하는 편두통 및 기타 질환 치료용 복합약
MY124465A (en) Reduction of infarct volume using citicoline
CA2537748A1 (en) Use of telmisartan for the prevention of vascular headache
EP0190851B1 (en) Improved antiinflammatory composition
Roy et al. Induction of theophylline toxicity and inhibition of clearance rates by ranitidine
NO974486L (no) Lavdoserte "Ridogrel"-formuleringer samt anvendelse derav ved behandling av tarmbetennelse
BE1002255A5 (fr) Medicaments.
KR900011461A (ko) 트립스타틴을 유효성분으로 하는 치료제
NL8105635A (nl) Geneesmiddel met transplantaatafstotings- en/of immunologische ontstekingsremmende werking, alsmede werkwijze voor de remming van transplantaatafstoting en/of immunologische ontsteking.
ATE91890T1 (de) Herstellung eines arzneimittels gegen arthritis und rheumatismus.
NZ315632A (en) Process for preparing solid dosage forms of very low-dose drugs comprising admixing 1-3% by weight of carrier particles with a solution of drug in water
IL117564A0 (en) Pharmaceutical and diagnostic compositions containing lysine derivatives
KR830008678A (ko) 진통 조성물
JPH0296521A (ja) 免疫性疾患治療剤
JPH07188040A (ja) 鼻炎治療用組成物
RU99112967A (ru) Способ лечения и профилактики дизентерии свиней